| ATRA, RAR-α agonists |
APL treatment; neuroblastoma treatment; skin disorders |
BC/MCF-7; AML/HL60, THP-1; APL/NB4, NB4-R2; NB/HTLA-230; GBM/U251; OC/A2780 CSC |
Decreases NRF2 binding to ARE sites; decreases NRF2 nuclear translocation |
[347–350] |
| PHA-767491 |
Cdc7/CDK9 inhibitor |
PDAC/PANC-1, Capan-1; HCC/HepG2 |
Decreases NRF2 nuclear translocation and activity |
[351] |
| Sorafenib |
Multi-Tyrosine kinase inhibitor; antiangiogenic therapy |
CRC/DLD-1, HCT116; TC/FTC133, BC-PAP, 8505C; RC/ACHN, 786-O; CRC/DLD-1; HCC/HepG2, BEL7402-5FU, HuH-7; BC/MCF7, MDA-MB-231; NSCLC/CALU-3 |
Decreases NRF2 expression and nuclear translocation |
[352] |
| Auranofin |
Rheumatoid arthritis |
NSCLC/Calu-3, Calu-6, H522 |
Decreases NRF2 activation |
[353] |
| Clobetasol Propionate |
Skin disorders |
NSCLC/A549, H2228 |
Decreases NRF2 nuclear accumulation and promotes β-TrCP-dependent NRF2 degradation |
[354] |
| Camptothecin |
Topoisomerase inhibitor; chemotherapy |
HCC/HepG2, SMMC-7721; NSCLC/A549 |
Decreases NRF2 expression |
[23] |
| Valproic acid |
Histone deacetylase inhibitor; epilepsy and seizure disorders; chemosensitizer |
BC/MCF7; TC/BCPAP, TCP1, BHP10-3 |
Decreases NRF2 nuclear content |
[355] |
| Metformin |
Antidiabetic drug |
BC/MCF-7; CRC/HT-29; EC/RL95–2, Spec-2, Ishikawa; HCC/HepG2; NSCLC/A549; CC/HeLa |
Decreases NRF2 mRNA and protein content; decreases NRF2 expression |
[356–361] |
| Isoniazid |
Antitubercular agent |
HCC/HepG2 |
Decreases NRF2 nuclear translocation |
[362] |
